Rajan Sharma: Hi, thanks for taking my questions. Just on the market of travel vaccine. So if you could just kind of help us understand what proportion of the revenue growth in 2022 was driven by volume versus price? And, how we should think about this dynamic into ’23 and into the mid-term? And then, secondly just again kind of the commercial vaccine business. There are some additional detail in today’s release which was helpful on growth margins. I am just wondering how we should think about this into 2023. Is it safe to assume that it’s kind of up ’22 levels? And what would be the pushes and pulls to this? And then just one follow-up on Lyme, in kind of a scenario where there is additional trials required, I just wanted to clarify if your potential contribution to those costs are capped at a certain level? Thanks.
Thomas Lingelbach: So, let me start with the Lyme section. And then, this gives the finance team bit more time to dig the numbers up. And so, I would say on Lyme — so first, you used the term addition studies. No, the study is ongoing. So, this means we have to study why it’s not stopped. So which means that there is — it’s only a matter of when do you recruit the necessary additional people into the study because you lost some of them. And the second part is, of course, related then to what kind of — do you keep a readout, and when do you do the readout. And this is always in relation to readout after primary immunization versus readout after priming class. So, that’s more from the clinical development point of view. On the cost side of things, we have not had any discussion yet about any potential incremental costs, and this is something that will be discussed as soon as we have an agreed development plan going forward.
Peter Buhler: Yes. And then, with regards to your volume versus price question, so when we look at the IXIARO as you can see on the slide, at constant exchange rate, we look at a downside of about 18.6% versus prior year. We are looking here the upside rate to price of a plus 10%, so, the differences of course, then volume-driven. When we look at DUKORAL, we have volume upside versus the prior year of roughly 400% and then the distance to the total 600% of services per year would be price-related. And I think you had a second question, but if you could just repeat that one.
Rajan Sharma: Yes, sure. It’s just on the gross margin on the travel vaccines; you have some additional information in the release today. And I was wondering whether those ’22 levels are kind of a fair assumption for margins going forward?
Thomas Lingelbach: Yes, so we look at a much stronger gross margin than for IXIARO then for DUKORAL in 2022. And, as you can see, the gross margin improved significantly versus prior year. And we would expect this improvement also to continue as we continue to increase volumes.
Rajan Sharma: Okay, that’s fair, that’s very helpful. Thank you.
Operator: Thank you. We’ll now take the next question. It comes from the line of Samir Devani from Rx Securities. Please go ahead. Your line is open.
